Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Sangamo Therapeutics Inc SGMO

Healthcare Biotechnology
Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company’s clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a... see more

Current News (NDAQ:SGMO)

Sangamo Therapeutics Initiates Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease

GlobeNewswire December 18, 2025

Sangamo Therapeutics Receives U.S. FDA Fast Track Designation for ST-503 for the Treatment of Small Fiber Neuropathy

GlobeNewswire December 2, 2025

Sangamo Therapeutics Announces FDA Acceptance of BLA Rolling Submission Request for ST-920 in Fabry Disease

GlobeNewswire November 21, 2025

Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2025 Financial Results

GlobeNewswire November 6, 2025

Sangamo Therapeutics Announces Third Quarter 2025 Earnings Call

GlobeNewswire October 30, 2025

Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at International Congress of Inborn Errors of Metabolism 2025

GlobeNewswire September 4, 2025

Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2025 Financial Results

GlobeNewswire August 7, 2025

Sangamo Therapeutics Announces Second Quarter 2025 Earnings Call

GlobeNewswire July 31, 2025

Sangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry Disease

Business Wire June 24, 2025
View More News ››

Opinion & Analysis (NDAQ:SGMO)

Sangamo Shares Trade 30% Higher on Q4 Earnings and Biogen Collaboration

Streetwise Reports March 2, 2020

Sangamo and Pfizer Report Positive Results for Hemophilia A Study

Streetwise Reports July 9, 2019

Investment in cell and gene therapies ramps up

The Life Sciences Report June 8, 2016

Big money to be made in biotech stocks

Andrew Mickey December 1, 2008
View More Opinion ››

Bullboard Posts (NDAQ:SGMO)

RE:Sold out of this stock today.

Nice call.  Yesterday was a disaster.  
Wheatkingtrad3r - January 1, 2025

Sold out of this stock today.

It was time for me to cash it out.It didn't go up too much,so that it was only $2.73 cents per share,but it was starting to churn...
coolfooldumbguy - December 17, 2024

Using technical analysis for this one.

Big buy for me at $2.23 cents per share this morning and it should keep climbing upward for a while,since this stock is a big bargain at...
coolfooldumbguy - December 16, 2024

Fabry gene disease therapy will save millions and millions

Expecting an announcement on Fabry disease partnership soon next week or so. Should give the stock a nice increase. Basically the cost...
askretka - November 1, 2024

8$ Target 28 October Jeffries Report

You can find it on stocktwits, don't have a link unfortunately.  Fabry deal expected soon to extend cash runway.  CHEERS!...
askretka - October 29, 2024

Up 36% today wow

Hope some people got onboard. Sorry  I was too busy to do a good post on it before it took off.  CHEERS!!!!!!!!!!!!!!!
askretka - October 28, 2024
View more Bullboard ››

Sorrento Resources Ltd.

Sorrento Resources Ltd.

Sorrento is engaged in acquisition, exploration, and development of mineral property assets in Canada. Sorrento’s objective ...
View More »

Podcasts